'Normal' thrombin generation

Blood

Volumn 94, Issue 7, 1999, Pages 2169-2178

  Butenas, Saulius ^a   Van't Veer, Cornelis ^a   Mann, Kenneth G ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN III; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 9; PROCOAGULANT; PROTEIN C; PROTEIN S; PROTHROMBIN; RECOMBINANT THROMBOPLASTIN; THROMBIN; THROMBOMODULIN; TISSUE FACTOR PATHWAY INHIBITOR;

ARTICLE; BLOOD CLOTTING TIME; CARDIOVASCULAR RISK; PRIORITY JOURNAL; REGULATORY MECHANISM; THROMBIN TIME; THROMBOSIS;

EID: 0033214353     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v94.7.2169.419k22_2169_2178     Document Type: Article

References (75)

1. Jenny NS, Mann KG: Coagulation cascade: An overview, in Loscalzo J, Schafer AI (eds): Thrombosis and Hemorrhage. Baltimore, MD, Williams & Wilkins, 1998, p 3
2. Beijering RJR, ten Cate H, ten Gate JW: Clinical applications of new antitihrombotic agents. Ann Hematol 72:177, 1996
3. Verstraete M: Modulating platelet function with selective thrombin inhibitors. Haemostasis 26:70, 1996 (suppl 4)
4. Schumacher WA, Steinbacher TE, Heran CL, Seiler SM, Michel IM, Ogletree ML: Comparison of thrombin active site and exosite inhibitors and heparin in experimental models of arterial and venous thrombosis and bleeding. J Pharmacol Exp Ther 267:1237, 1993
5. Kyrle PA, Mannhalter C, Beguin S, Stumpften A, Hirschl M, Weltermann A, Stain M, Brenner B, Speiser W, Pabinger I, Lechner K, Eichinger S: Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene. Arterioscler Thromb Vasc Biol 18:1287, 1998
6. Cui J, O'Shea KS, Purkayastha A, Saunders TL, Ginsburg D: Fatal haemorrhage and incomplete block to embryogenesis in mice lacking coagulation factor V. Nature 384:66, 1996
7. Degen SJ, Sun WY: The biology of prothrombin. Crit Rev Eukaryot Gene Expr 8:203, 1998
8. Rosen ED, Chan JC, Idusogie E, Clotman F, Vlasuk G, Luther T, Jalbert LR, Albrecht S, Zhong L, Lissens A, Schoonjans L, Moons L, Collen D, Castellino FJ, Carmeliet P: Mice lacking factor VII develop normally but suffer fatal perinatal bleeding. Nature 390:290, 1997
9. Kundu RK, Sangiorgi F, Wu LY, Kurachi K, Anderson WF, Maxson R, Gordon EM: Targeted inactivation of the coagulation factor IX gene causes hemophilia B in mice. Blood 92:168, 1998
10. Chiu HC, Whitaker E, Colman RW: Heterogeneity of human factor V deficiency. Evidence for the existence of an antigen-positive variants. J Clin Invest 72:493, 1983
11. Poort SR, Michiels JJ, Reitsma PH, Bertina RM: Homozygosity for a novel missense mutation in the prothrombin gene causing a severe bleeding disorder. Thromb Haemost 72:819, 1994
12. Ragni MV, Lewis JH, Spero JA, Hasiba U: Factor VII deficiency. Am J Hematol 10:79, 1981
13. McGraw RA, Davis LM, Lundblad RL, Stafford DW, Roberts HR: Structure and function of factor IX: Defects in haemophilia B. Clin Haematol 14:359, 1985
14. Hoyer LW: Hemophilia A. N Engl J Med 330:38, 1994
15. Trimble M, Bell DA, Brien W, Hachinski V, O'Keefe B, McLay C, Black J: The antiphospholipid syndrome: Prevalence among patients with stroke and transient ischemic attacs. Am J Med 88:593, 1990
16. Ozsoylu S, Ozer FL: Acquired factor IX deficiency. Acta Haematol 50:305, 1973
17. Broekmans AW, Veltkamp JJ, Bertina RM: Congenital protein C deficiency and venous thromboembolism. A study of three Dutch families. N Engl J Med 309:340, 1983
18. Comp PC, Esmon CT: Recurrent venous thromboembolism in patients with a partial deficiency of protein S. N Engl J Med 311:1525, 1984
19. Vigano-D'Angelo S, D'Angelo A, Kaufman CE Jr, Sholer C, Esmon CT, Comp PC: Protein S deficiency occurs in the nephrotic syndrome. Ann Intern Med 107:42, 1987
20. Scott BD, Esmon CT, Comp PC: The natural anticoagulant protein S is decreased in male smokers. Am Heart J 122:76, 1991
21. Sporrong T, Mattsson LA, Samsioe G, Stigendal L, Hellgren M: Haemostatic changes during continuous oestradiol-progestogen treatment of postmenopausal women. Br J Obstet Gynaecol 97:939, 1990
22. Egeberg O: Proceedings: Inherited antithrombin III deficiency and thromboembolism. Thromb Diath Haemorrh 34:366, 1975
23. Harper PL, Luddington RJ, Daly M, Bruce D, Williamson D, Edgar PF, Perry DJ, Carrell RW: The incidence of dysfunctional antithrombin variants: Four cases in 210 patients with thromboembolic disease. Br J Haematol 77:360, 1991
24. Coller BS, Owen J, Jesty J, Horowitz D, Reitman MJ, Spear J, Yen T, Comp PC: Deficiency of plasma protein S, protein C, or antithrombin III and arterial thrombosis. Arteriosclerosis 7:456, 1987
25. Gibbons GH: The vascular response to injury, in Loscalzo J, Schafer AI (eds): Thrombosis and Hemorrhage. Baltimore, MD, Williams & Wilkins, 1998, p 307
26. Tracy PB, Nesheim ME, Mann KG: Coordinate binding of factor Va and factor Xa to the unstimulated platelet. J Biol Chem 256:743, 1981
27. Walsh PN: Platelet coagulant activities and hemostasis: An hypothesis. Blood 43:597, 1974
28. Tollefsen DM, Majerus DW, Blank MK: Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. J Biol Chem 257:2162, 1982
29. Travis J, Salvesen GS: Human plasma proteinase inhibitors. Annu Rev Biochem 52:655, 1983
30. Butenas S, van't Veer C, Mann KG: Evaluation of the initiation phase of blood coagulation using ultrasensitive assays for serine proteases. J Biol Chem 272:21527, 1997
31. Girard TJ, Warren LA, Novotny WF, Likert KM, Brown SG, Miletich JP, Broze GJ Jr: Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 338:518, 1989
32. van't Veer C, Mann KG: Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III, and heparin cofactor-II. J Biol Chem 272:4367, 1997
33. Rosenberg RD: The heparin-antithrombin system: A natural anticoagulant, in Colman RW, Hirsh J, Marder VJ, Salzman EW (eds): Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia, PA, Lippincott, 1987, p 1373
34. van't Veer C, Golden NJ, Kalafatis M, Mann KG: Inhibitory mechanism of the protein C pathway on tissue factor-induced thrombin generation. J Biol Chem 272:7983, 1997
35. Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM, Powers P: Development of the human coagulation system in the full-term infant. Blood 70:165, 1987
36. Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L: Maturation of the hemostatic system during childhood. Blood 80:1998, 1992
37. Lawson JH, Kalafatis M, Stram S, Mann KG: A model for the tissue factor pathway to thrombin. I. An empirical study. J Biol Chem 269:23357, 1994
38. Jones KC, Mann KG: A model for the tissue factor pathway to thrombin. II. A mathematical simulation. J Biol Chem 269:23367, 1994
39. Beltrami E, Jesty J: Mathematical analysis of activation thresholds in enzyme-catalyzed positive feedbacks: Application to the feedbacks of blood coagulation. Proc Natl Acad Sci USA 92:8744, 1995
40. Jesty J, Beltrami E, Willems G: Mathematical analysis of a proteolytic positive-feedback loop: dependence of lag time and enzyme yields on the initial conditions and kinetic parameters. Biochemistry 32:6266, 1993
41. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM: A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88:3698, 1996
42. Bovill EG, Bauer KA, Dickerman JD, Callas P, West B: The clinical spectrum of heterozygous protein C deficiency in a large New England kindred. Blood 73:712, 1989
43. Schwarz HP, Fischer M, Hopmeier P, Batard MA, Griffin JH: Plasma protein S deficiency in familial thrombotic disease. Blood 64:1297, 1984
44. Woodward M, Lowe GD, Rumley A, Tunstall-Pedoe H, Philippou H, Lane DA, Morrison CE: Epidemiology of coagulation factors, inhibitors and activation markers: The Third Glasgow MONICA Survey. II. Relationships to cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol 97:785, 1997
45. Higgins DL, Mann KG: The interaction of bovine factor V and factor V-derived peptides with phospholipid vesicles. J Biol Chem 258:6503, 1983
46. Bajaj SP, Rapaport SI, Prodanos C: A simplified procedure for purification of human prothrombin, factor IX and factor X. Prep Biochem 11:397, 1981
47. Katzmann JA, Nesheim ME, Hibbard LS, Mann KG: Isolation of functional human coagulation factor V by using a hybridoma antibody. Proc Natl Acad Sci USA 78:162, 1981
48. Griffith MJ, Noyes CM, Church FC: Reactive site peptide structural similarity between heparin cofactor II and antithrombin III. J Biol Chem 260:2218, 1985
49. Dahlback B: Purification of human vitamin K-dependant protein S and its limited proteolysis by thrombin. Biochem J 209:837, 1983
50. Cawthern KM, van't Veer C, Lock JB, DiLorenzo ME, Branda RF, Mann KG: Blood coagulation in hemophilia A and hemophilia C. Blood 91:4581, 1998
51. Mustard JF, Perry DW, Ardlie NG, Packham MA: Preparation of suspension of washed platelets from humans. Br J Haematol 22:193, 1972
52. Rand MD, Lock JB, van't Veer C, Gaffney DP, Mann KG: Blood clotting in minimally altered whole blood. Blood 88:3432, 1996
53. Krishnaswamy S, Church WR, Nesheim ME, Mann KG: Activation of human prothrombin by human prothrombinase. Influence of factor Va on the reaction mechanism. J Biol Chem 262:3291, 1987
54. Nesheim ME, Tracy RP, Mann KG: "Clotspeed", a mathematical simulation of the functional properties of prothrombinase. J Biol Chem 259:1447, 1984
55. Stone SR, Hermans JM: Inhibitory mechanism of serpins. Interaction of thrombin with antithrombin and protease nexin 1. Biochemistry 34:5164, 1995
56. de Moerloose P, Wutschert R, Heinzmann M, Perneger T, Reber G, Bounameaux H: Superficial vein thrombosis of lower limbs: Influence of factor V Leiden, factor II G20210A and overweight. Thromb Haemost 80:239, 1998
57. Doggen CJ, Cats VM, Bertina RM, Rosendaal FR: Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation 97:1037, 1998
58. Makris M, Preston FE, Beauchamp NJ, Cooper PC, Daly ME, Hampton KK, Bayliss P, Peake RI, Miller GJ: Co-inheritance of the 20210A allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia. Thromb Haemost 78:1426, 1997
59. Arruda VR, Annichino-Bizzacchi JM, Goncalves MS: Prevalence of the prothrombin gene variant (nt2021 OA) in venous thrombosis and arterial disease. Thromb Haemost 78:1430, 1997
60. Bovill EG, Hasstetd SJ, Callas PW, Valliere JE, Scott BT, Bauer KA, Long GI: The G20210A prothrombin polymorphism is not associated with increased risk of venous throbmboembolic disease. Blood:92, 755, 1998 (suppl 1, abstr)
61. Zivelin A, Rao LVM, Rapaport SI: Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin K-dependent clotting factors. J Clin Invest 92:2131, 1993
62. Roberts HR, Bingham MD: Other coagulation factor deficiencies, in Loscalzo J, Schafer AI (eds): Thrombosis and Hemorrhage. Baltimore, MD, Williams & Wilkins, 1998, p 773
63. Lechner K, Niessner H, Thaler E: Coagulation abnormalities in liver disease. Semin Thromb Hemost 4:40, 1977
64. Soff GA, Levin J: Familial multiple coagulation factor deficiencies. Semin Thromb Hemost 7:112, 1981
65. McMillan CW, Roberts HR: Congenital combined deficiency of coagulation factors II, VII, IX and X. N Engl J Med 274:1313, 1966
66. Brenner B, Tavori S, Zivelin A, Keller CB, Suttie JW, Tatarsky I, Seligsohn U: Hereditary deficiency of all vitamin K-dependent procoagulants and anticoagulants. Br J Haematol 75:537, 1990
67. Komiyama Y, Pedersen AH, Kisiel W: Proteolytic activation of human factors IX and X by recombinant human factor VIIa: Effects of calcium, phospholipids, and tissue factor. Biochemistry 29:9418, 1990
68. van't Veer C, Golden NJ, Mann KG: Paradoxical inhibition of thrombin generation by the zymogen factor VII. Circulation 94:4333, 1996 (suppl, abstr)
69. Novotny WF: Tissue factor pathway inhibitor. Semin Thromb Hemost 20:101, 1994
70. Broze GJ Jr, Lange GW, Duffin KL, Macphail L: Heterogeneity of plasma tissue factor pathway inhibitor. Blood Coagul Fibrinolysis 5:551, 1994
71. LEIDEN. J Biol Chem 272:20721, 1997
72. van't Veer C, Golden NJ, Mann KG: Regulation of prothrombinase activity by protein S. Thromb Haemost: 186, 1997 (suppl)
73. Miletich J, Sherman L, Broze G Jr: Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 317:991, 1987
74. Hasstedt SJ, Bovill EG, Callas PW, Long GL: An unknown genetic defect increases venous thrombosis risk, through interaction with protein C deficiency. Am J Hum Genet 63:569, 1998
75. Kalafatis M, Egan JO, van't Veer C, Cawthern KM, Mann KG: The regulation of clotting factors. Crit Rev Eukaryot Gene Expr 7:241, 1997